Trials / Completed
CompletedNCT03877055
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but this is the first time that they are being given together.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Copanlisib | Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles. |
| DRUG | Ibrutinib | Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy. |
Timeline
- Start date
- 2019-03-13
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
- First posted
- 2019-03-15
- Last updated
- 2022-12-14
- Results posted
- 2022-12-14
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03877055. Inclusion in this directory is not an endorsement.